Article By:
Moon Kil Woong
Monday, October 18, 2021 3:30 PM EDT
Vaccine makers have been under tremendous selling pressure over the past 2 months driven by policy, the rising delta wave, and breakthrough infections. This slump has been a boost for the oral antivirals
In this article: AZN, JNJ, LLY, MRK, PFE, SNY, INO, RHHBY, NVAX, REGN, GILD, MRNA, AVIR, TOMDF, BNTX, CVAC
